BACKGROUND: Triple-negative (TN) breast cancer lacks a known signaling pathway amenable to targeted therapy. The authors hypothesized that the G protein-coupled receptor GPR30 may be present in TN breast cancer and serve a role for tumor growth. METHODS: A retrospective pathology study and chart review were conducted. All patients aged ≤49 years from 2000 to 2008 were included (n = 24). Concurrent patients aged ≥50 years were randomly selected. Paraffin sections were stained for GPR30 and reviewed by a pathologist blinded to estrogen receptor and progesterone receptor status. Disease-free survival was analyzed versus age and receptor status. Means were compared using 2-sample t tests and proportions using chi-square analysis. RESULTS: Twenty-seven patients tested GPR30 positive and 21 GPR30 negative. Seventeen of 18 TN cancers tested positive for GPR30 (P < .0001). Recurrence at a mean follow-up of 36 months was 22.2% in the GPR30-positive group and 9.5% in the GPR30-negative group. CONCLUSIONS: GPR30 is prevalent in TN breast cancer and associated with young age and possibly recurrence.
BACKGROUND: Triple-negative (TN) breast cancer lacks a known signaling pathway amenable to targeted therapy. The authors hypothesized that the G protein-coupled receptor GPR30 may be present in TN breast cancer and serve a role for tumor growth. METHODS: A retrospective pathology study and chart review were conducted. All patients aged ≤49 years from 2000 to 2008 were included (n = 24). Concurrent patients aged ≥50 years were randomly selected. Paraffin sections were stained for GPR30 and reviewed by a pathologist blinded to estrogen receptor and progesterone receptor status. Disease-free survival was analyzed versus age and receptor status. Means were compared using 2-sample t tests and proportions using chi-square analysis. RESULTS: Twenty-seven patients tested GPR30 positive and 21 GPR30 negative. Seventeen of 18 TN cancers tested positive for GPR30 (P < .0001). Recurrence at a mean follow-up of 36 months was 22.2% in the GPR30-positive group and 9.5% in the GPR30-negative group. CONCLUSIONS:GPR30 is prevalent in TN breast cancer and associated with young age and possibly recurrence.
Authors: Tapan K Nayak; Chinnasamy Ramesh; Helen J Hathaway; Jeffrey P Norenberg; Jeffrey B Arterburn; Eric R Prossnitz Journal: Mol Cancer Res Date: 2014-07-16 Impact factor: 5.852
Authors: Hilary T Magruder; Jeffrey A Quinn; Jean E Schwartzbauer; Jonathan Reichner; Allan Huang; Edward J Filardo Journal: Horm Cancer Date: 2014-08-06 Impact factor: 3.869